invoX CEO Ben Toogood (L) and F-star CEO Eliot Forster
July 8, 2022 09:17 AM EDTUpdated 03:02 PM
Deals
Bioregnum

A por­trait of a biotech buy­out deal in sav­age times: turn­ing a $15.50 of­fer in­to a $7.12 deal

Back last No­vem­ber, the once high-fly­ing F-star was hurt­ing, bad. Its share price had been crushed and the CEO, Eliot Forster of Im­muno­core fame, had …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Judge halts some NIH cuts af­ter 22 states sue

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

Decade af­ter $8B deal, Roche of­floads In­ter­Mune to mys­te­ri­ous spe­cial­ty phar­ma

Eli Lil­ly inks $630M deal for Phase 1 MASH can­di­date

Boehringer In­gel­heim touts suc­cess in sec­ond Phase 3 lung fi­bro­sis tri­al

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times